Lenalidomide and Dexamethasone for Treatment of Patients With Acute Myeloma (Light Chain)-Induced Renal Failure.
Phase of Trial: Phase II
Latest Information Update: 04 Mar 2017
At a glance
- Drugs Dexamethasone (Primary) ; Lenalidomide (Primary)
- Indications Multiple myeloma
- Focus Therapeutic Use
- Acronyms LD
- 24 Nov 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 02 Jun 2012 Company added in association field as reported by European Clinical Trials Database.
- 20 Mar 2012 Company (Celgene Corporation) added as trial sponsor/affiliate as reported by European Clinical Trials Database record.